{"nctId":"NCT01151098","briefTitle":"Safety of Buprenorphine Transdermal Systems in Subjects With Chronic Nonmalignant Pain - a 28-week Extension Study","startDateStruct":{"date":"2001-04"},"conditions":["Chronic Nonmalignant Pain"],"count":189,"armGroups":[{"label":"BTDS 5, 10 or 20","type":"EXPERIMENTAL","interventionNames":["Drug: Buprenorphine transdermal patch"]}],"interventions":[{"name":"Buprenorphine transdermal patch","otherNames":["Butransâ„¢"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nInclude:\n\n* Subjects of either sex aged 18 years or older.\n* Subjects who have completed or discontinued the double-blind evaluation phase of study BUP3201 are eligible to continue to receive open-label BTDS in the extension.\n\nExclusion Criteria:\n\nInclude:\n\n* Subjects currently receiving daily morphine or oxycodone (mono-therapy).\n* Subjects who are discontinued from BUP3201 due to adverse events.\n* Subjects who are scheduled for surgery of the disease site (e.g. major joint replacement surgery) or any other major surgery which would fall within the study period.\n\nRefer to core study for additional inclusion/exclusion information.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Adverse Events (AEs) as a Measure of Safety.","description":"Safety was assessed using reports of all new adverse events (AEs) that occurred after the first application of a patch during the extension phase were recorded.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"143","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":16,"n":189},"commonTop":["Erythema at site","Pruritus at site","Rash at site","Nausea","Somnolence"]}}}